One fifth of Europe's biopharma firms "at risk of bankruptcy"
This article was originally published in Scrip
The European biotechnology industry is calling for urgent action at both EU and national levels after a new study suggested that a fifth of small European biopharmaceutical companies could be facing bankruptcy by the end of the year as a result of the global financial crisis.
You may also be interested in...
Panelists at a recent virtual session of the DIA’s Europe 2020 conference identified the positive and negative aspects of Europe’s response to the pandemic, and suggested ways of avoiding shortages and making the supply chain more resilient in the event of future crises.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.